Last reviewed · How we verify
SOC 4F-PCC
SOC 4F-PCC is a Factor IIa protease-activated receptor 1 (PAR-1) antagonist that inhibits thrombin signaling to reduce thrombotic events.
SOC 4F-PCC is a Factor IIa protease-activated receptor 1 (PAR-1) antagonist that inhibits thrombin signaling to reduce thrombotic events. Used for Acute coronary syndrome (Phase 3).
At a glance
| Generic name | SOC 4F-PCC |
|---|---|
| Sponsor | Takeda |
| Drug class | PAR-1 antagonist |
| Target | PAR-1 (Protease-Activated Receptor 1) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
The drug blocks PAR-1, a G-protein coupled receptor activated by thrombin, which plays a key role in platelet activation and thrombosis. By antagonizing PAR-1, SOC 4F-PCC reduces pathological clot formation while potentially preserving hemostasis. This mechanism is distinct from conventional anticoagulants and antiplatelet agents.
Approved indications
- Acute coronary syndrome (Phase 3)
Common side effects
- Bleeding
- Dyspnea
Key clinical trials
- A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SOC 4F-PCC CI brief — competitive landscape report
- SOC 4F-PCC updates RSS · CI watch RSS
- Takeda portfolio CI